Program
sacituzumab tirumotecan
Also written as “Sacituzumab tirumotecan”, “SKB264” and “Sacituzumab Tirumotecan”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Breast Neoplasms · Ovarian Neoplasms · Endometrial Neoplasms, led by 4 companies.
Drug pageSacituzumab tirumotecan: every studyAll 113 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 2928 open or running | phase 3since Oct 3, 2023 | Apr 1, 2022 | May 10, 2027phase 3 · NCT06074588 |
| Sichuan Kelun Pharmaceuticalits history only | 1716 open or running | phase 3since Apr 15, 2022 | Apr 15, 2022 | Nov 2026phase 3 · NCT06448312 |
| Klus Pharmaits history only | 33 open or running | phase 2since Oct 29, 2019 | Oct 29, 2019 | Nov 30, 2027phase 2 · NCT05642780 |
| Convalife (Shanghai)its history only | 11 open or running | phase 2since Aug 22, 2025 | Aug 22, 2025 | Aug 12, 2028phase 2 · NCT07157956 |
- Named in Merck’s own pipeline as
sacituzumab tirumotecan (MK-2870)
, phase 4, as of Nov 2, 2026 (source).
Also a collaborator on its studies: Daiichi Sankyo and Myriad Genetics.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseMerck licensed it from Kelun-Biotech, for everywhere outside Greater China.Source: Merck, Nov 4, 2025
How Klus Pharma and Convalife (Shanghai) relate to it is not in the registry or these sources.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 11 earlier studies, Apr 1, 2022 to May 15, 2024.
- Aug 6, 2023Named sacituzumab tirumotecanINNProposed as its International Nonproprietary Name in WHO's List 129 · before, SKB264
- May 20, 20242 phase 2 studiesNCT06428409, NCT06445972
- Jun 10, 2024Phase 3 study in Uterine Cervical NeoplasmsNCT06459180 · 686 enrolled · United States, Argentina, Australia and more
- Jun 17, 20242 phase 2 studiesNCT06469944, NCT06483334
- Oct 9, 2024Phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT06637423 · 35 enrolled · United States, Canada, France and more
- Jan 13, 20252 phase 2 studiesNCT06780111, NCT06788912
- Feb 7, 20252 phase 3 studiesNCT06824467, NCT06841354
- Apr 23, 2025Phase 3 study in Endometrial NeoplasmsNCT06952504 · 1,123 planned · United States, Argentina, Australia and more
- May 4, 2025Phase 3 study in Breast NeoplasmsNCT06966700 · 2,400 planned · United States, Argentina, Australia and more
- Oct 10, 2025Phase 3 study in Uterine Cervical NeoplasmsNCT07216703 · 1,023 planned · United States, Argentina, Austria and more
- Nov 20, 2025Phase 2 study in NeoplasmsNCT07252739 · 140 planned · United States, Chile, China and more
- Jan 2, 2026Phase 3 study in Ovarian NeoplasmsNCT07318558 · 900 planned · United States, Argentina, Australia and more
- Feb 10, 2026Phase 3 study in Urinary Bladder NeoplasmsNCT07419295 · 590 planned · United States, Argentina, Australia and more
- Sep 15, 2026Phase 3 study in Urinary Bladder NeoplasmsNCT07829783 · 400 planned · Taiwan, Ukraine
- Oct 26, 2026Phase 2 study in Metastatic Castration-resistant Prostate CancerNCT07908524 · 290 planned
Ahead
- May 10, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06074588
- Jun 11, 2027Primary completion: phase 2 study in Esophageal Squamous Cell CarcinomaNCT05319730
- Jul 11, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT06312176
- Dec 31, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06049212
TargetBeta
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugate…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) ”NCIt, by rule
Other programs on TACSTD2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sacituzumab govitecanrule | Gilead Sciences | phase 4 | 30 |
| datopotamab deruxtecanrule | AstraZeneca | phase 3 | 29 |
| JSKN016rule | Alphamab Oncology | phase 3 | 5 |
| Anti-TROP2 Antibody-drug Conjugate ESG401rule | Qilu Pharmaceutical | phase 3 | 3 |
| Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036Crule | Minghui Pharmaceutical | phase 2 | 3 |
| sacituzumab drozuntecanrule | dualitybio-inc | phase 2 | 2 |
| Anti-TROP-2 Antibody-drug Conjugate OBI-902rule | obi-pharma-inc | phase 2 | 1 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998rule | Astellas Pharma | phase 2 | 1 |
| JSKN016HCrule | Alphamab Oncology | phase 1 | 1 |
| KH815rule | Chengdu Kanghong Pharmaceutical Group | phase 1 | 1 |
Studies
All 29 Merck leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07908524Metastatic Castration-resistant Prostate Cancer | 2 | Not yet recruiting | Jun 29, 2032 | 290 |
| NCT07829783Urinary Bladder Neoplasms · Taiwan, Ukraine | 3 | Recruiting | Nov 17, 2031 | 400 |
| NCT07419295Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Jul 27, 2029 | 590 |
| NCT07318558Ovarian Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Feb 25, 2033 | 900 |
| NCT07252739Neoplasms · United States, Chile, China and more | 2 | Recruiting | Nov 15, 2029 | 140 |
| NCT07216703Uterine Cervical Neoplasms · United States, Argentina, Austria and more | 3 | Recruiting | Oct 29, 2031 | 1,023 |
| NCT06966700Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Mar 23, 2033 | 2,400 |
| NCT06952504Endometrial Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | May 24, 2032 | 1,123 |
| NCT06841354Triple Negative Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | May 18, 2030 | 1,000 |
| NCT06824467Ovarian Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Apr 27, 2029 | 770 |
| NCT06788912Lung Neoplasms · United States, Chile, Greece and more | 2 | Active, not recruiting | Feb 6, 2032 | 60 |
| NCT06780111Esophageal Squamous Cell Carcinoma · United States, Brazil, Chile and more | 2 | Recruiting | Jan 4, 2032 | 298 |
| NCT06637423Non-Muscle Invasive Bladder Neoplasms · United States, Canada, France and more | 2 | Completed | Sep 30, 2026 | 35 |
| NCT06483334Carcinoma, Transitional Cell · United States, Canada, France and more | 2 | Active, not recruiting | Mar 31, 2028 | 38 |
| NCT06469944Esophageal Neoplasms · United States, Brazil, Chile and more | 2 | Recruiting | Sep 12, 2029 | 160 |
| NCT06459180Uterine Cervical Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jun 15, 2028 | 686 |
| NCT06445972Esophageal Neoplasms · United States, Brazil, Chile and more | 2 | Recruiting | May 9, 2028 | 210 |
| NCT06428409Colorectal Neoplasms · United States, Australia, Canada and more | 2 | Recruiting | Oct 16, 2029 | 220 |
| NCT06422143Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more | 3 | Recruiting | Jan 12, 2029 | 851 |
| NCT06393374Triple Negative Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Dec 16, 2030 | 1,530 |
| NCT06356311Adenocarcinoma Of Esophagus · United States, Belgium, Brazil and more | 3 | Active, not recruiting | Oct 19, 2026 | 473 |
| NCT06312137Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Feb 21, 2034 | 780 |
| NCT06312176Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Jul 11, 2027 | 1,200 |
| NCT06305754Carcinoma, Non-Small-Cell Lung · United States, Argentina, Canada and more | 3 | Active, not recruiting | Aug 17, 2028 | 550 |
| NCT06170788Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Jan 25, 2028 | 614 |
| NCT06132958Endometrial Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 10, 2028 | 710 |
| NCT06074588Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more | 3 | Active, not recruiting | May 10, 2027 | 556 |
| NCT06049212Carcinoma, Non-Small-Cell Lung · Japan | 1 | Active, not recruiting | Dec 31, 2027 | 30 |
| NCT05319730Esophageal Squamous Cell Carcinoma · United States, Brazil, Chile and more | 2 | Recruiting | Jun 11, 2027 | 230 |
How it is read
Names in the registry
- “Sacituzumab tirumotecan”, 22 entries
- “SKB264”, 15 entries
- “Sacituzumab Tirumotecan”, 5 entries
- “SKB264+SKB118”, 2 entries
- “sac-TMT”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 14 studies
- Triple Negative Breast Neoplasms, 6 studies
- Breast Neoplasms, 3 studies
- Ovarian Neoplasms, 2 studies
- Endometrial Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.